Light-activated therapies—such as photodynamic therapy (PDT), photothermal therapy (PTT), photoimmunotherapy (PIT), and photo-initiated tissue crosslinking—offer an exceptional level of spatial precision in medicine. By using light as a remote trigger, clinicians can theoretically activate toxic drugs, generate localized heat, or solidify hydrogels precisely where the light is directed, sparing surrounding healthy tissue.
However, the clinical utility of these modalities is fundamentally bottlenecked by a harsh physical reality: the limited penetration depth of light through biological tissue.
The Physical Bottleneck of Light Attenuation
When photons travel through biological layers like skin, fat, muscle, or bone, they do not travel in a straight line, nor do they pass through unimpeded. Instead, they undergo severe scattering and absorption by endogenous chromophores such as hemoglobin, melanin, and water.
The severity of this attenuation depends heavily on the wavelength of the light:
- Visible Light (400–700 nm): Wavelengths in this spectrum are scattered so intensely by cellular structures and absorbed so strongly by blood components that they can only penetrate a few millimeters into tissue. As noted by Chao Chen et al. and Yuandou Wang, this restricts visible-light-triggered systems to superficial pathologies or areas accessible via invasive optical instruments.
- Near-Infrared Light (NIR-I, 700–900 nm): Often referred to as the "biological window," NIR-I light experiences lower absorption, allowing it to travel deeper. Yet, even NIR-I lasers attenuate rapidly, losing effective therapeutic energy within a few centimeters or even millimeters of tissue (Tingting Zhang et al., Jiaqi Meng et al.).
Light Wavelength vs. Tissue Penetration Depth (Conceptual)
===================================================================
Ultraviolet / Visible Light (400-700 nm) --> | [Tissue Surface] (Imm-few mm)
Near-Infrared I (700-900 nm) ----> | | (Few mm-1-2 cm)
Near-Infrared II (1000-1700 nm) ----------> | | | (Several cm)
X-Rays / Internal Cerenkov Radiation -------------------------> [Deep Tissue]
===================================================================
This depth limitation creates a severe clinical mismatch. While phototherapies work exceptionally well in small animal models (where a tumor is rarely more than a few millimeters beneath the skin), scaling them to human anatomy is incredibly difficult.
Non-invasive phototherapies are largely restricted to superficial skin infections or surface malignancies (Guangzhi Wu et al., Junhua Fu et al.). For deep-seated internal organs or malignancies shielded by dense bone—such as glioblastoma in the brain—external lasers simply cannot deliver enough photon flux to activate photosensitizers or photothermal agents (Hao Wu et al., Xiaojun Wang et al.).
To bypass this barrier, clinicians must resort to invasive delivery methods, such as surgically inserting fiber-optic probes or endoscopes directly into the target site (Yue Yan et al., Vinit Kumar Malik, Jinliang Han). Furthermore, the therapeutic reach of photoimmunotherapy is heavily dependent on tumor size; as a tumor grows, its core becomes physically shielded from external light, leaving deep-seated or metastatic lesions untouched (Weijun Wei et al.). This constraint similarly limits the utility of light-activated tissue adhesives in deep internal surgeries (Yaoting Xue et al.).
To overcome these physical constraints, researchers have developed three primary strategies: shifting the optical window, generating light internally, and engineering multimodal synergies.
Strategy 1: Shifting to the NIR-II Window
The most direct way to improve penetration depth without losing the non-invasive nature of phototherapy is to shift the excitation light to longer wavelengths, specifically the second near-infrared window (NIR-II, 1000–1700 nm).
The intuition behind this shift is rooted in the physics of tissue scattering. Rayleigh and Mie scattering describe how light scatters off particles and structures that are smaller than or comparable to its wavelength. Crucially, tissue scattering decreases monotonically as the wavelength increases ($S \propto \lambda^{-b}$, where $b$ is a tissue-specific scattering exponent).
By engineering nanomaterials—such as upconversion nanoparticles, gold nanorods, or covalent organic frameworks—that absorb and respond to NIR-II light, researchers can exploit this reduced scattering to deliver energy significantly deeper into solid tissues (Weili Wang et al., Wenze Xu et al., Liang Zhang et al.). However, while the NIR-II window dramatically mitigates scattering, it does not completely eliminate photon attenuation in large-scale human tissues, meaning that extremely deep targets may still face energy deficits (Yucheng Huang et al.).
Strategy 2: Internal and Self-Powered Photon Generation
Instead of trying to force external photons through centimeters of absorbing tissue, a more radical strategy bypasses external lasers entirely by generating light directly inside the target site. This is the core principle behind Radio-Dynamic Therapy (RDT).
High-energy radiation, such as X-rays, passes through the human body with minimal attenuation. When these high-energy rays travel through a medium at a speed greater than the speed of light in that medium, they polarize the surrounding molecules, which then snap back into place and release brief flashes of blue/UV light. This phenomenon is known as Cerenkov radiation.
Radio-Dynamic Therapy (RDT) Mechanism
===================================================================
[External X-Ray Source]
│
▼ (Deep, unattenuated tissue penetration)
[Deep-Seated Tumor Site]
│
├─► Tissue Interaction ──► Generates Cerenkov Light (In Situ Photons)
│ │
▼ ▼
[Nanoagents / Photosensitizers] ◄───────────┘ (Local Activation)
│
▼
[Therapeutic Response / Cell Death]
===================================================================
As demonstrated by Guiping Xiao et al., RDT leverages deep-penetrating X-rays to generate Cerenkov light in situ. Because this photon flux is generated directly next to the co-delivered photosensitizers, it completely circumvents the optical penetration barrier.
Similarly, researchers are exploring self-powered or internally triggered nanomedicines that harvest the tumor's own metabolic abnormalities—such as high lactate levels or specific intracellular enzymes—to drive therapeutic cascades without requiring an external light source to penetrate the tissue barrier (Xiaojun Wang et al.).
Strategy 3: Multimodal Hybridization and Microenvironment Priming
A third approach accepts the physical decay of light at depth and compensates for it by pairing phototherapy with deep-penetrating, non-optical modalities. By creating hybrid systems, the shallow but highly precise action of light can be used to prime a tissue, while a deeper-reaching energy source finishes the therapeutic task.
- Interventional Hybridization: For example, Fengrong Zhang et al. developed an interventional strategy that pairs photothermal therapy with brachytherapy (internal radiation seeds) to treat deep pancreatic cancer. The localized heat from the phototherapy sensitizes the tumor cells to radiation, allowing a lower, safer dose of radiation to achieve maximum efficacy deep within the organ.
- Microenvironment-Activated Cascades: To maximize the impact of the few photons that do manage to reach a deep target, nanoagents can be engineered with dual-trigger mechanisms. These "smart" molecules remain completely dormant until they encounter both a specific tumor biomarker (such as hypoxia or high hydrogen peroxide levels) and the target light wavelength (Yi Pan et al., Jinliang Han). This dual-gating mechanism ensures that even if a weak, attenuated light signal reaches the deep tissue, the therapeutic effect is amplified by the local biochemistry, preventing off-target side effects in healthy tissues where the biomarker is absent.
Key Foundational Work
AIEgen-based theranostic system: targeted imaging of cancer cells and adjuvant amplification of antitumor efficacy of paclitaxel (2016) — contributed 2 concept elements to this direction.
A redox-activated theranostic nanoagent: toward multi-mode imaging guided chemo-photothermal therapy (2018) — contributed 1 concept elements to this direction.